These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Wilcock GK; Ballard CG; Cooper JA; Loft H J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023 [TBL] [Abstract][Full Text] [Related]
8. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506 [TBL] [Abstract][Full Text] [Related]
9. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. Ballard C; Corbett A; Orrell M; Williams G; Moniz-Cook E; Romeo R; Woods B; Garrod L; Testad I; Woodward-Carlton B; Wenborn J; Knapp M; Fossey J PLoS Med; 2018 Feb; 15(2):e1002500. PubMed ID: 29408901 [TBL] [Abstract][Full Text] [Related]
11. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. Herrmann N; Cappell J; Eryavec GM; Lanctôt KL CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613 [TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121 [TBL] [Abstract][Full Text] [Related]
13. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG; Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380 [TBL] [Abstract][Full Text] [Related]
16. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study). Yoon SJ; Choi SH; Na HR; Park KW; Kim EJ; Han HJ; Lee JH; Shim YS; Na DL Geriatr Gerontol Int; 2017 Mar; 17(3):494-499. PubMed ID: 27111084 [TBL] [Abstract][Full Text] [Related]
17. Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia. Meunier J; Creel K; Loubert A; Larsen KG; Aggarwal J; Hefting N; Oberdhan D Front Neurol; 2024; 15():1379062. PubMed ID: 39108660 [TBL] [Abstract][Full Text] [Related]
18. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial. Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476 [TBL] [Abstract][Full Text] [Related]